Ovid Therapeutics (OVID) Other Operating Expenses (2016 - 2023)
Ovid Therapeutics' (OVID) quarterly Other Operating Expenses came in at -$1000.0 in Q1 2023, down 100.48% YoY from $209050.0 in Q1 2022, and down 100.12% on a QoQ basis from $836085.0 in Q3 2022.
Ovid Therapeutics (OVID) Other Operating Expenses (2016 - 2023) Analysis & Trends
Ovid Therapeutics (OVID) has 8 years of Other Operating Expenses data on file, last reported at -$1000.0 in Q1 2023.
- Quarterly Other Operating Expenses fell 100.48% year-over-year to -$1000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was -$1000.0 (down 100.13% YoY) and the FY2021 annual result came in at -$45690.0, down 111.56% from the prior year.
- Other Operating Expenses slipped to -$1000.0 in Q1 2023, from $836085.0 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $836085.0 in Q3 2022 to a low of -$438260.0 in Q4 2020.
- A 5-year average of $109971.6 and a median of $3280.0 in 2021 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2019 — Other Operating Expenses jumped 58195.11% — and 2022, when it slumped 11188.32%.
- Tracing OVID's Other Operating Expenses over 5 years: stood at $298720.0 in 2019, then tumbled by 246.71% to -$438260.0 in 2020, then soared by 100.89% to $3903.0 in 2021, then soared by 21321.6% to $836085.0 in 2022, then tumbled by 100.12% to -$1000.0 in 2023.
- The last three Other Operating Expenses figures came in at -$1000.0 (Q1 2023), $836085.0 (Q3 2022), and -$284127.0 (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -1,000.00 |
| Sep 30, 2022 | 836,085.00 |
| Jun 30, 2022 | -284,127.00 |
| Mar 31, 2022 | 209,050.00 |
| Dec 31, 2021 | 3,903.00 |
| Sep 30, 2021 | 2,657.00 |
| Jun 30, 2021 | -2,517.00 |
| Mar 31, 2021 | -49,732.00 |
| Dec 31, 2020 | -438,260.00 |
| Sep 30, 2020 | -21,127.00 |
| Jun 30, 2020 | 590,491.00 |
| Mar 31, 2020 | 264,296.00 |
| Dec 31, 2019 | 298,720.00 |
| Sep 30, 2019 | 131,164.00 |
| Dec 31, 2018 | -10,296.00 |
| Sep 30, 2018 | 225.00 |
| Jun 30, 2018 | 304.00 |
| Mar 31, 2018 | 136.00 |
| Dec 31, 2017 | -63.00 |
| Sep 30, 2017 | -112.00 |